KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to -$1.8 billion.

  • Abbott Laboratories' Cash from Financing Activities fell 1167.51% to -$1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.8 billion, marking a year-over-year decrease of 2105.45%. This contributed to the annual value of -$5.4 billion for FY2024, which is 2379.07% up from last year.
  • According to the latest figures from Q3 2025, Abbott Laboratories' Cash from Financing Activities is -$1.8 billion, which was down 1167.51% from -$1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Abbott Laboratories' Cash from Financing Activities peaked at -$791.0 million during Q2 2024, and registered a low of -$3.8 billion during Q1 2022.
  • Over the past 5 years, Abbott Laboratories' median Cash from Financing Activities value was -$1.5 billion (recorded in 2022), while the average stood at -$1.6 billion.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 29534.64% in 2022, then surged by 6311.8% in 2023.
  • Quarter analysis of 5 years shows Abbott Laboratories' Cash from Financing Activities stood at -$1.9 billion in 2021, then grew by 22.75% to -$1.5 billion in 2022, then crashed by 40.84% to -$2.1 billion in 2023, then increased by 9.31% to -$1.9 billion in 2024, then grew by 5.43% to -$1.8 billion in 2025.
  • Its Cash from Financing Activities was -$1.8 billion in Q3 2025, compared to -$1.1 billion in Q2 2025 and -$2.1 billion in Q1 2025.